Literature DB >> 19656130

Activation of the JAK/STAT pathway in Epstein Barr virus+-associated posttransplant lymphoproliferative disease: role of interferon-gamma.

M Vaysberg1, S L Lambert, S M Krams, O M Martinez.   

Abstract

Epstein Barr virus (EBV) is associated with B-cell lymphomas in posttransplant lymphoproliferative disease (PTLD). Latent membrane protein 1 (LMP1), the major oncogenic protein of EBV, promotes tumorigenesis through activation of NF-kappaB, Erk, p38, JNK and Akt. The Jak/STAT signal transduction pathway is also constitutively active in PTLD-associated EBV(+) B-cell lymphomas. Here we determine the mechanism of Jak/STAT activation in EBV(+) B-cell lymphomas and the role of LMP1 in this process. Immunoprecipitation studies revealed no direct interaction of LMP1 and JAK3, but known associations between JAK3 and common gamma chain, and between LMP1 and TRAF3, were readily detected in EBV(+) B cell lines from patients with PTLD. An inducible LMP1 molecule expressed in EBV(-) BL41 Burkitt's cells demonstrated STAT activation only after prolonged LMP1 signaling. While LMP1 induced IFN-gamma production in BL41 cells, IFN-gamma receptor blockade and IFN-gamma neutralization prior to LMP1 activation markedly decreased STAT1 activation and expression of LMP1-driven IFN-gamma inducible genes. Understanding the mechanisms by which EBV induces cellular signal transduction pathways may facilitate development of new treatments for PTLD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19656130      PMCID: PMC2774223          DOI: 10.1111/j.1600-6143.2009.02781.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  31 in total

1.  Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus.

Authors:  Takashi Nakayama; Kunio Hieshima; Daisuke Nagakubo; Emiko Sato; Masahiro Nakayama; Keisei Kawa; Osamu Yoshie
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

2.  Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling.

Authors:  Christopher W Dawson; Giorgos Tramountanis; Aristides G Eliopoulos; Lawrence S Young
Journal:  J Biol Chem       Date:  2002-11-21       Impact factor: 5.157

Review 3.  The role of the cyclin-dependent kinase inhibitor p21 in apoptosis.

Authors:  Andrei L Gartel; Angela L Tyner
Journal:  Mol Cancer Ther       Date:  2002-06       Impact factor: 6.261

4.  The SH2 domains of Stat1 and Stat2 mediate multiple interactions in the transduction of IFN-alpha signals.

Authors:  S Gupta; H Yan; L H Wong; S Ralph; J Krolewski; C Schindler
Journal:  EMBO J       Date:  1996-03-01       Impact factor: 11.598

Review 5.  The role of CXC chemokines as regulators of angiogenesis.

Authors:  R M Strieter; P J Polverini; D A Arenberg; S L Kunkel
Journal:  Shock       Date:  1995-09       Impact factor: 3.454

6.  The Epstein-Barr virus latent membrane protein 1 putative Janus kinase 3 (JAK3) binding domain does not mediate JAK3 association or activation in B-lymphoma or lymphoblastoid cell lines.

Authors:  Masaya Higuchi; Elliott Kieff; Kenneth M Izumi
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

7.  Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions.

Authors:  K Shuai; C M Horvath; L H Huang; S A Qureshi; D Cowburn; J E Darnell
Journal:  Cell       Date:  1994-03-11       Impact factor: 41.582

8.  Expression of immune-related molecules in primary EBV-positive Chinese nasopharyngeal carcinoma: associated with latent membrane protein 1 (LMP1) expression.

Authors:  Jiang Li; Xiao-Shi Zhang; Dan Xie; Hai-Xia Deng; Yan-Fang Gao; Qiu-Yan Chen; Wen-Lin Huang; Maria G Masucci; Yi-xin Zeng
Journal:  Cancer Biol Ther       Date:  2007-10-13       Impact factor: 4.742

9.  Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas.

Authors:  Ronald R Nepomuceno; Cynthia E Balatoni; Yaso Natkunam; Andrew L Snow; Sheri M Krams; Olivia M Martinez
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

10.  Human Mig chemokine: biochemical and functional characterization.

Authors:  F Liao; R L Rabin; J R Yannelli; L G Koniaris; P Vanguri; J M Farber
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  16 in total

Review 1.  EBV-associated lymphomas in adults.

Authors:  Mark Roschewski; Wyndham H Wilson
Journal:  Best Pract Res Clin Haematol       Date:  2012-02-05       Impact factor: 3.020

Review 2.  Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

Review 3.  Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention.

Authors:  Abhik Saha; Rajeev Kaul; Masanao Murakami; Erle S Robertson
Journal:  Cancer Biol Ther       Date:  2010-11-15       Impact factor: 4.742

Review 4.  Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein-Barr Virus-Associated Malignancies.

Authors:  Xueyi Zheng; Yuhua Huang; Kai Li; Rongzhen Luo; Muyan Cai; Jingping Yun
Journal:  Viruses       Date:  2022-05-10       Impact factor: 5.818

5.  The pathology of epstein-barr virus lymphoproliferations.

Authors:  Stefan D Dojcinov; Matthew R Pugh
Journal:  Hemasphere       Date:  2019-06-30

6.  Mutational profile and EBV strains of extranodal NK/T-cell lymphoma, nasal type in Latin America.

Authors:  Ivonne A Montes-Mojarro; Bo-Jung Chen; Ana F Ramirez-Ibarguen; Carmen M Quezada-Fiallos; Wendy B Pérez-Báez; Daniela Dueñas; Sandro Casavilca-Zambrano; Marcela Ortiz-Mayor; Erica Rojas-Bilbao; Hernan García-Rivello; Maria F Metrebian; Marina Narbaitz; Carlos Barrionuevo; Carmen Lome-Maldonado; Irina Bonzheim; Falko Fend; Julia Steinhilber; Leticia Quintanilla-Martinez
Journal:  Mod Pathol       Date:  2019-12-10       Impact factor: 7.842

7.  Epstein - Barr virus Latent Membrane Protein 1 suppresses reporter activity through modulation of promyelocytic leukemia protein-nuclear bodies.

Authors:  Mark D Sides; Gregory J Block; Reid W Chadwick; Bin Shan; Erik K Flemington; Joseph A Lasky
Journal:  Virol J       Date:  2011-10-05       Impact factor: 4.099

Review 8.  Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?

Authors:  J Morscio; D Dierickx; T Tousseyn
Journal:  Clin Dev Immunol       Date:  2013-04-14

9.  Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways.

Authors:  Harumi Kato; Kennosuke Karube; Kazuhito Yamamoto; Jun Takizawa; Shinobu Tsuzuki; Yasushi Yatabe; Teru Kanda; Miyuki Katayama; Yukiyasu Ozawa; Kenji Ishitsuka; Masataka Okamoto; Tomohiro Kinoshita; Koichi Ohshima; Shigeo Nakamura; Yasuo Morishima; Masao Seto
Journal:  Cancer Sci       Date:  2014-04-09       Impact factor: 6.716

10.  Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders.

Authors:  Elizabeth Margolskee; Vaidehi Jobanputra; Preti Jain; Jinli Chen; Karthik Ganapathi; Odelia Nahum; Brynn Levy; Julie Morscio; Vundavalli Murty; Thomas Tousseyn; Bachir Alobeid; Mahesh Mansukhani; Govind Bhagat
Journal:  Oncotarget       Date:  2016-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.